fda - Search News

FDA Approves 1st Non-Opioid Pain Drug in 20 Years

FDA approves first new type of pain medication in 25 years

A new pain relief drug, suzetrigine, is a prescription pill that’s taken every 12 hours after a larger starter dose. It will be sold under the brand name Journavx.

Hosted on MSN · 8h

FDA approves painkiller designed to eliminate the risk of addiction associated with opioids

Federal officials on Thursday approved a new type of pain pill designed to eliminate the risks of addiction and overdose associated with opioid medications like Vicodin and OxyContin. The U.S. Food and Drug Administration said it approved Vertex Pharmaceuticals' Journavx for short-term pain that often follows surgery or injuries.

Time on MSN · 9h

FDA Approves the First Non-Opioid Pain Drug in 20 Years

The prescription pills, sold under the brand name Journavx and made by Vertex Pharmaceuticals, are taken twice a day and represent the first new class of pain medications in 20 years—and the first non-opioid painkiller since that class first appeared on the market in the 1980s.

Ozempic receives FDA nod for treating chronic kidney disease

CNN on MSN · 2d

FDA approves Ozempic to reduce risks from chronic kidney disease in diabetes patients

Ozempic, the blockbuster GLP-1 drug that was originally approved to treat type 2 diabetes, has now also been approved by the US Food and Drug Administration to reduce certain risks associated with chronic kidney disease,

U.S. News & World Report · 1d

FDA Approves Ozempic to Protect Kidneys in Patients With Type 2 Diabetes

Doctors already use Ozempic to manage type 2 diabetes and reduce the risk of heart disease in patients with diabetes. This move, as reported by The Times, was based on research sh

Hosted on MSN · 1d

Ozempic receives FDA nod for treating chronic kidney disease; experts explain how diabetes drug reduces CKD risk

The US Food and Drug Administration (FDA) approval is based on the clinical trials that showed how Ozempic, the diabetes drug, showed a reduced risk of kidney failure. Experts explain how the drug helps.

FDA upgrades recall of Lay's potato chips

Newsweek on MSN · 1d

Chocolate Recall Update As FDA Sets Highest Risk Level for 9 States

A recall which was issued across nine states has now been given the highest risk classification by the federal agency.

Fortune on MSN · 1d

FDA reclassifies Lay’s potato chips recall to the highest risk level, warning the chips could cause ‘serious adverse health consequences or death’

The FDA has raised the risk level on a recall of Lay’s potato chips to the highest level, warning the recalled product could cause death. The chips were originally recalled last month for containing undeclared milk.

USA Today · 1d

Lay's potato chips recall upgraded to FDA's most serious level. Is Ohio affected?

The FDA elevated Lay's Classic Potato Chips to the highest risk level. Here what to know, and whether the recall impacts Ohio.

10h

US FDA approves Axsome Therapeutics' migraine drug

The U.S. Food and Drug Administration has approved Axsome Therapeutics' migraine treatment, the company said on Thursday.

2don MSN

Trump admin's FDA withdraws proposed federal rule to ban menthol cigarettes

Trump's FDA moved to squash a proposed rule to ban menthol cigarettes just one day after the president was sworn in, angering ...

cnbctv1828m

Biocon Biologics CEO expects core margin improvement, outlines upcoming launches

Alongside margin recovery, Biocon Biologics has also gained market share, with oncology remaining a key focus area.

Moscow-Pullman Daily News51m

New bill introduced to put 10-year pause on certain vaccines

BOISE — Sen. Brandon Shippy, R-New Plymouth, is proposing to put a 10-year pause on certain types of vaccines that were used ...

Opinion

Williamsport Sun-Gazette1hOpinion

What other newspapers are saying: Pharmacy benefit practices must be reformed

In 2021, the FDA approved a new insulin drug, Semglee, that was interchangeable with a brand-name insulin called Lantus. Lantus cost $292 for a 30-day supply. Drugmaker Viatris launched two versions ...

4hon MSN

Intel's reliance on US funding is a symptom of its problems, says analyst

Ed Snyder of Charter Equity Research reacts to Intel's latest set of earnings, saying government help will not be enough to help turn the company's fortunes around.

Results that may be inaccessible to you are currently showing.

Hide inaccessible results

FDA Approves 1st Non-Opioid Pain Drug in 20 Years

Ozempic receives FDA nod for treating chronic kidney disease

FDA upgrades recall of Lay's potato chips

Related topics